1235451-65-6

Basic information

• Product Name: BenzenaMine, 5-broMo-2-(2-broMoethoxy)-
• Synonyms: BenzenaMine, 5-broMo-2-(2-broMoethoxy)-;5-Bromo-2-(2-bromoethoxy)aniline
• CAS NO: 1235451-65-6
• Molecular Formula: C₈H₉Br₂NO
• Molecular Weight: 294.97116
• Mol File: 1235451-65-6.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: BenzenaMine, 5-broMo-2-(2-broMoethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: BenzenaMine, 5-broMo-2-(2-broMoethoxy)-(1235451-65-6)
• EPA Substance Registry System: BenzenaMine, 5-broMo-2-(2-broMoethoxy)-(1235451-65-6)

Safety Data

• Hazardous Substances Data: 1235451-65-6(Hazardous Substances Data)

Upstream product

• 40925-68-6 2-amino-4-bromo-phenol 
• 106-93-4 ethylene dibromide 
• 1101858-58-5 4-bromo-1-(2-bromoethoxy)-2-nitrobenzene 

Downstream Products

• 719310-31-3 tert-butyl 6-bromo-2,3-dihydrobenzo[b][1,4]oxazine-4-carboxylate 
• 105655-01-4 6-bromo-3, 4-dihydro-2H-benzo[β][1, 4]oxazine 

Relevant articles and documents

PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH ZINC BINDING MOIETY

PROBLEM TO BE SOLVED: To provide phosphoinositide 3-kinase inhibitors with a zinc binding moiety. SOLUTION: There is provided a compound represented by formula (I) in the figure. (X is S, O or the like; Y is CH, N or the like; G1 is optionally substituted N or the like; R1 and R2 are each independently H or the like; C is a substituted heterocycle or the like; B is a linear alkyl or the like; Ra and Rb together with the nitrogen atom coupled to them are morpholino or the like; G2 is an indazole ring or the like; q, r and s are independently from 0 to 1, provided that at least one of them is 1; t is from 0 to 1; n is from 0 to 4; and p is from 0 to 2.) COPYRIGHT: (C)2016,JPOandINPIT

TREATMENT OF CANCERS HAVING K-RAS MUTATIONS

The present invention provides a method of treating a cancer associated with a K-ras mutation in a subject in need thereof. The method comprises the steps of: (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) administering to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.

TREATMENT OF CANCERS HAVING K-RAS MUTATIONS

The present invention provides a method of treating a cancer associated with a K- ras mutation in a subject in need thereof. The method comprises the steps of (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) adminsiterign to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.

Dual-target-directed 1,3-diphenylurea derivatives: BACE 1 inhibitor and metal chelator against Alzheimer's disease

Dual-target-directed 1,3-diphenylurea derivatives were designed by hybridizing BACE 1 inhibitor 1 with metal chelator LR-90. A database consisted of 1,3-diphenylurea derivatives was built and screened by the pharmacophore model (Hypo 1) of BACE 1 inhibitor. Based on the predicted results, 11 compounds (6a-d, 9a-g) with favorable Fitvalues were selected, synthesized and evaluated for their BACE 1 inhibitory activities, which showed that the predicted results were in good agreement with the experimental values. Besides, the synthesized compounds also displayed the ability to chelate metal ions. The most effective BACE 1 inhibitor 9f (27.85 ± 2.46 μmol/L) was selected for further receptor-binding studies, the result of which indicated that an essential hydrogen bonds was formed between the urea group of 9f and the catalytic aspartate Asp228.